RAPP today
$25.85-$1.17 (-4.33%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourBearish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns up above $52.93
Key levels
Resistance$28.59
Resistance$26.36
Support$22.95
Support$20.22
Latest news & SEC filings
AnalystUBS keeps Buy rating on Rapport Therapeutics, cuts price target to $64
AnalystAnalysts adjust their views on Rapport Therapeutics stock
AnalystGuggenheim keeps Buy rating on Rapport Therapeutics, cuts target to $66
All RAPP news →About Rapport Therapeutics
Rapport Therapeutics is a biotech firm in the clinical testing phase that creates targeted oral drugs for brain and mental health conditions. Its main candidate, RAP-219, aims to treat certain forms of epilepsy and bipolar mania by acting on a specific brain protein. The company is also exploring treatments for pain, migraine, and inner ear balance issues. It is based in the United States and licenses some technology from Janssen.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
Rapport Therapeutics, Inc. (RAPP)
What Is the Price Target for RAPP?
SEPT Low Target
$50.00
SEPT Mid Target
$66.00
SEPT High Target
$89.00
Analyst Consensus
$66.00
Is RAPP a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RAPP.
Start Free Trial →Is RAPP Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$55.14
12
Moat Score
NONE
2/9
Piotroski Score
20.0
Altman Z-Score
What Is Smart Money Doing with RAPP?
Insider Signal
NEUTRAL
11 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | director 10% owner | Buy | 238,095 | $5.0M | Oct 30, 2026 |
| Third Rock Ventures V, L.P. | director 10% owner | Buy | 1,190,476 | $25.0M | Oct 30, 2026 |
| HEALY JAMES | director | Buy | 952,380 | $20.0M | Oct 28, 2026 |
| HEALY JAMES | director | Buy | 6,395 | $134K | Oct 28, 2026 |
| HEALY JAMES | director | Buy | 3,772 | $79K | Oct 28, 2026 |
| HEALY JAMES | director | Buy | 6,933 | $146K | Oct 28, 2026 |
| Sanchez Ramiro | director | Buy | 3,600 | $98K | Oct 23, 2026 |
| Silva Paul M | director | Buy | 3,680 | $100K | Oct 22, 2026 |
| PAUL STEVEN M | director | Buy | 35,714 | $974K | Oct 22, 2026 |
| MARAGANORE JOHN | director | Buy | 8,239 | $217K | Oct 22, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RAPP Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
24.34%
FCF Growth YoY
-31.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for RAPP
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RAPP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:10 | $25.85 | 1,640 | $$42K | SELL |
| 21:00:10 | $25.85 | 1,000 | $$26K | SELL |
| 21:00:10 | $25.85 | 1,300 | $$34K | SELL |
| 21:00:00 | $25.85 | 1,028 | $$27K | BUY |
| 20:30:44 | $26.15 | 1,000 | $$26K | BUY |
5 dark pool trades shown · $$155K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RAPP
PREVIEWSEPT Investing provides real-time options flow tracking for RAPP, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $27.5 | Dec 18 | 36 | $$232 | 1 | SWEEP |
| CALL | $27.5 | Nov 20 | 8 | $$77 | 1 | SWEEP |
| CALL | $27.5 | Dec 18 | 36 | $$232 | 1 | SWEEP |
| CALL | $27.5 | Nov 20 | 8 | $$77 | 1 | SWEEP |
| CALL | $27.5 | Dec 18 | 36 | $$232 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About RAPP
5 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for RAPP. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $PETV — LOWENTHAL GARRY N | Sale $5K $CURB — Lukes David R | Sale $RAPP — Sanchez Ramiro | Sale $98K $ACA — DEMETRIOU STEVEN J. | Sale $1.9M $ACA — Carrillo Antonio | Sale
Smart Money Moves $PETV — LOWENTHAL GARRY N | Sale $5K $CURB — Lukes David R | Sale $RAPP — Sanchez Ramiro | Sale $98K $ACA — DEMETRIOU STEVEN J. | Sale $1.9M $ACA — Carrillo Antonio | Sale
Smart Money Moves $PETV — LOWENTHAL GARRY N | Sale $5K $CURB — Lukes David R | Sale $RAPP — Sanchez Ramiro | Sale $98K $ACA — DEMETRIOU STEVEN J. | Sale $1.9M $ACA — Carrillo Antonio | Sale
Join 3,500+ traders discussing RAPP in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Rapport Therapeutics, Inc. (RAPP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RAPP — frequently asked questions
What is RAPP stock price today?
Rapport Therapeutics, Inc. (RAPP) is at $25.85, down 4.33% (-$1.17) at the Nov 12, 2026 close.
Why is RAPP stock moving today?
Latest RAPP news — Nov 5, 2026: UBS keeps Buy rating on Rapport Therapeutics, cuts price target to $64 · Nov 5, 2026: Analysts adjust their views on Rapport Therapeutics stock
What is the RAPP price target?
The average analyst price target for RAPP is $66.00, ranging from $50 to $89, based on 9 analysts. Latest: Guggenheim raises on Oct 22, 2026.
What do analysts rate RAPP?
Analyst ratings for RAPP: 0 Buy, 20 Hold, 0 Sell — consensus Hold.
Did RAPP beat earnings?
RAPP last reported on Aug 5, 2026: EPS -$1.19 vs -$0.96 expected — a miss of 23.6%.
Does RAPP pay a dividend?
RAPP does not currently pay a dividend.
What are RAPP support and resistance levels?
Support: $22.95, $20.22, $17.99. Resistance: $26.36, $28.59, $31.58.
What are insiders doing with RAPP?
Insider activity: NEUTRAL, 11 buys and 9 sells in the last 90 days.
What is the latest news on RAPP?
Nov 5, 2026: UBS keeps Buy rating on Rapport Therapeutics, cuts price target to $64 · Nov 5, 2026: Analysts adjust their views on Rapport Therapeutics stock · Nov 5, 2026: Guggenheim keeps Buy rating on Rapport Therapeutics, cuts target to $66